Aromatase inhibitors (AIs) are a cornerstone of adjuvant therapy for hormone receptor–positive breast cancer, significantly reducing recurrence and mortality. However, by suppressing estrogen ...

Denosumab use was associated with a lower risk for incident diabetes among patients with osteoporosis. Denosumab use is associated with a lower risk for diabetes among patients with osteoporosis, ...

A real-world cohort study finds that denosumab use is linked to a lower risk for incident knee osteoarthritis in adults with osteoporosis than the use of bisphosphonates.

Please provide your email address to receive an email when new articles are posted on . Adults with osteoporosis who received more than one dose of denosumab had a reduced risk for developing diabetes ...

Denosumab may reduce fracture risk, but increase cardiovascular risks in patients on dialysis. Denosumab may reduce fracture risk better than oral bisphosphonates for treatment of osteoporosis in ...

Please provide your email address to receive an email when new articles are posted on . Compared with oral bisphosphonate use, denosumab use was associated with a 45% lower risk for fractures among ...

Compared with oral bisphosphonates, denosumab reduced fracture risk among treatment-experienced postmenopausal women with osteoporosis. Treatment with denosumab vs oral bisphosphonates is associated ...

Continued denosumab treatment is associated with a lower risk for diabetes in adults with osteoporosis older than 65 years, found a large-scale cohort study in Taiwan. Denosumab, used in osteoporosis ...

Our news journalists obtained a quote from the research from Optum, "Potential denosumab 60 mg off-label use was observed based on claims, but many had evidence of on-label indications based on ...

Basel, March 5, 2024 – Sandoz, the global leader in generic and biosimilar medicines, today announced that the US Food and Drug Administration (FDA) approved Wyost® (denosumab-bbdz) and Jubbonti® ...

Fresenius announced today that its operating company Fresenius Kabi, has introduced two new biosimilars - Conexxence® (denosumab-bnht) and Bomyntra® (denosumab-bnht) - in the United States. This press ...